Online Inquiry


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Anti-CS1 CAR-T Preclinical in vivo Assay

Target Background

CS1 or SLAMF7, CD319 is a cell-surface glycoprotein, which is manifested as a robust marker in CD138-purified primary tumor cells from the majority of multiple myeloma (MM) patients, while exists at low levels on normal NK cells, some T-cell subsets, plasma cells (PCs) and almost undetectable on myeloid cells and the majority of other healthy tissues, especially hematopoietic stem cells. Pathological augment of CS1 may cooperate with CD138 to promote MM cell adhesion, clonogenic growth, and tumorigenicity via c-Maf-mediated interaction with bone marrow stromal cells. Since CS1 is highly and nearly ubiquitously expressed on MM cells other than normal cells especially the hematopoietic stem cells, CS1-targeted cytotoxic leukocytes will not impair major immune cell subsets, which makes anti-CS1 CAR-T a promising immunotherapy.

SLAMF7 interactive network

SLAMF7 interactive network
Diagram created by Creative Biolabs based on the online tool from Nucleic acids research 37.suppl 1 (2009): D412-D416

Anti-CS1 CAR-T Cell Therapy

As a humanized anti-CS1 monoclonal IgG1 antibody, Elotuzumab (HuLuc63) is found to inhibit myeloma cell adhesion to the bone marrow stromal cell, subsequently, induce NK cell-mediated antibody-dependent cellular cytotoxicity and promote NK cell activation without killing autologous NK cells. The efficiency study of anti-MM in preclinical models and several phase 1/2 clinical trials (NCT00742560, NCT00726869, and NCT00425347) has manifested the therapeutic potential of targeting CS1 for the treatment of MM. Therefore, anti-CS1 CAR-T cell immunotherapy will be a promising mean to augment the anti-MM capacity in the near future. Creative Biolabs is dedicated to assisting researchers to initiate and develop the cutting-edge anti-CS1 CAR-T cell therapy.

Animal Models for in vivo Study of anti-CS1 CAR-T Cell Therapy

As an almost incurable plasma-cell malignancy, MM is characterized by osteolytic bone disease and immunosuppression. Creative Biolabs provides multiple murine models of MM for the better understanding of the elusive pathogenesis and the unceasing development of novel therapeutic strategies. The MM animal models of Creative Biolabs are generated from the major techniques including the conventional carcinogen-induction (such as pristine oil), the mosaic transposon- or virus-induction, the transgenesis and the subcutaneous or patient-derived xenograft (such as 5T2MM, 5T33). In addition, Creative Biolabs also assists customers in creating clinically relevant animal models including but not limited to the above categories. You request, Creative Biolabs offers the best.

In vivo Assay Parameters and Techniques

At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical CS1 CAT-T cell therapy research.
Efficacy Test
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking.
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Toxicity Evaluation
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Tumorigenicity study

Creative Biolabs outperforms the entire biotechnological community to back researchers with every resource for establishing the most reliable and subtle animal models in advance to help the customer achieve incredible disproportionate results and exponentially greater value. Creative Biolabs assists researchers in making the scientific history.


  1. Hsi, Eric D., et al. "CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma." Clinical Cancer Research 14.9 (2008): 2775-2784.
  2. Jensen, Lars J., et al. "STRING 8—a global view on proteins and their functional interactions in 630 organisms." Nucleic acids research 37.suppl 1 (2009): D412-D416.
  3. Yu, Jianhua, Craig Hofmeister, and Jianhong Chu. "Cs1-specific chimeric antigen receptor engineered immune effector cells." U.S. Patent Application No. 14/888,877.

All services and products are only for lab research use, not for any clinical diagnosis or treatment.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.